20+ Leading Malignant Mesothelioma Pipeline Companies are working to improve the Treatment Landscape

DelveInsight's, "Malignant Mesothelioma Pipeline Insight, 2023," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Malignant Mesothelioma pipeline landscape. It covers the Malignant Mesothelioma pipeline drug profiles, including Malignant Mesothelioma clinical trials and nonclinical stage products. It also covers the Malignant Mesothelioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

For Malignant Mesothelioma emerging drugs, the Malignant Mesothelioma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Malignant Mesothelioma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

In the Malignant Mesothelioma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Malignant Mesothelioma clinical trial studies, Malignant Mesothelioma NDA approvals (if any), and product development activities comprising the technology, Malignant Mesothelioma collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.

Key takeaways from the Malignant Mesothelioma Pipeline Report

• Over 20+ Malignant Mesothelioma companies are evaluating 20+ Malignant Mesothelioma pipeline therapies in various stages of development, and their anticipated acceptance in the Malignant Mesothelioma market would significantly increase market revenue.

• The leading Malignant Mesothelioma Companies includes Epizyme, Ys Therapeutics, Novartis, Bayer, RS Oncology, Polaris Pharmaceuticals, Merck, Vivace Therapeutics, Shionogi, Mirati Therapeutics, Incyte Corporation, TCR2 Therapeutics, SOTIO Biotech, Pfizer, Ascentage Pharma, Fida Farmaceutici, and others.

• Promising Malignant Mesothelioma Pipeline Therapies includes Nivolumab, Ipilimumab, Pemetrexed, MTG201, Nivolumab Injection [Opdivo], Tremelimumab, THOR-707, Gemcitabine, Durvalumab, Cisplatin, Vorinostat, and others.
• The Malignant Mesothelioma companies and academics are working to assess challenges and seek opportunities that could influence in Malignant Mesothelioma R&D. The Malignant Mesothelioma pipeline therapies under development are focused on novel approaches to treat/improve in Malignant Mesothelioma.

Request a sample and discover the recent breakthroughs happening in Malignant Mesothelioma pipeline landscape, click here for Malignant Mesothelioma Pipeline Outlook Report @ https://www.delveinsight.com/sample-request/malignant-mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Malignant Mesothelioma Overview
Malignant mesothelioma is a rare growth of mesothelial cells strongly associated with asbestos exposure. Mesothelial cells form the lining layers of the viscera. Mesothelioma can occur at any mesothelial layer such as the peritoneum or pericardium. The pleural layer is by far the most commonly affected, giving rise to malignant pleural mesothelioma. The risk of developing mesothelioma was described as 10% over the lifetime of an asbestos worker, with up to 70% of all mesothelioma cases involving documented asbestos exposure. Signs and symptoms associated with mesothelioma are relatively nonspecific and can be seen with almost any intrathoracic disease process, benign or malignant. Most patients have a cough, usually nonproductive. Dyspnea is also common. Chest wall pain may be a relatively unique symptom, usually described as a focal ache. There may be palpable soft tissue fullness or mass and decreased respiratory sounds with dullness to percussion due to an underlying pleural effusion. Some patients develop splinting and even scoliosis toward the ipsilateral side.

Recent Developmental Activities in the Malignant Mesothelioma Treatment Landscape

• In April 2022, Ascentage Pharma announced that the combination of palbociclib and APG-2449 synergistically inhibits tumor growth in mesothelioma and such effect is mediated by induced autophagy and enhanced cellular senescence. The preclinical study suggests that APG-2449 combined with CDK4/6 inhibitors may have therapeutic potential in mesothelioma and may warrant future clinical development.

• In July 2021, The FDA granted an orphan drug designation to the anticancer drug paclitaxel-hyaluronic acid (Oncofid-P) for the treatment of malignant mesothelioma, according to a press release by Fida Farmaceutici.

Explore more information on the latest breakthroughs in the Malignant Mesothelioma treatment landscape of the report, click here for Malignant Mesothelioma Pipeline Outlook @ https://www.delveinsight.com/sample-request/malignant-mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Malignant Mesothelioma Emerging Drugs Profile

• INCB001158: Incyte Corporation
INCB001158 (CB-1158) is an investigational first-in-class, novel small molecule arginase inhibitor. Arginase is an enzyme that suppresses the immune-mediated destruction of tumors by depleting levels of a key amino acid, L-arginine, from the tumor microenvironment. A number of cell types in the tumor microenvironment, including myeloid-derived suppressor cells, macrophages, and neutrophils, can secrete arginase. L-arginine deprivation can act via nutrient sensor pathways to exert several suppressive effects on T-cell function, inhibiting proliferation, decreasing cytokine production, and diminishing expression of the T-cell receptor CD3ζ chain. Arginase activity may thus impair T-cell mediated anti-tumor responses

• RSO-021: RS Oncology
RSO-021 is a novel irreversible inhibitor of a key mitochondrial enzyme PRX3 (upregulated in cancer cells) regulating oxidative stress pathways. Treatment with RSO-021 will be administered weekly via an intrapleural catheter after routine pleural effusion drainage.

• Pegargiminase: Polaris Pharmaceuticals
Pegargiminase (ADI-PEG 20) is a potential first-in-class targeted cancer therapy in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma (HCC) and malignant pleural mesothelioma (MPM). Pegargiminase is well tolerated, both as a monotherapy and as part of a combination therapy.

Malignant Mesothelioma Pipeline Therapeutics Assessment
There are approx. 20+ key companies which are developing the therapies for Malignant Mesothelioma. The companies which have their Malignant Mesothelioma drug candidates in the most advanced stage, i.e. Phase III include, Polaris Pharmaceuticals.

For further information, refer to the detailed Malignant Mesothelioma Unmet Needs, Malignant Mesothelioma Market Drivers, and Malignant Mesothelioma Market Barriers, click here for Malignant Mesothelioma Ongoing Clinical Trial Analysis @ https://www.delveinsight.com/sample-request/malignant-mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Malignant Mesothelioma Segmentation

Phases
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
• Intravenous
• Intramuscular
• Oral
• Subcutaneous

Molecule Type
• Small Molecule
• Gene Therapy
• Stem Cell Therapy
• Antidepressants

Discover more about the list of Malignant Mesothelioma FDA-approved drugs for Malignant Mesothelioma, click here for Malignant Mesothelioma Treatment Landscape @ https://www.delveinsight.com/sample-request/malignant-mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Malignant Mesothelioma Pipeline Report
• Coverage- Global

• Malignant Mesothelioma Companies- Epizyme, Ys Therapeutics, Novartis, Bayer, RS Oncology, Polaris Pharmaceuticals, Merck, Vivace Therapeutics, Shionogi, Mirati Therapeutics, Incyte Corporation, TCR2 Therapeutics, SOTIO Biotech, Pfizer, Ascentage Pharma, Fida Farmaceutici, and others.

• Malignant Mesothelioma Pipeline Therapies- Nivolumab, Ipilimumab, Pemetrexed, MTG201, Nivolumab Injection [Opdivo], Tremelimumab, THOR-707, Gemcitabine, Durvalumab, Cisplatin, Vorinostat, and others.

• Malignant Mesothelioma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Dive deep into rich insights for Malignant Mesothelioma Emerging Therapies and Malignant Mesothelioma Ongoing Clinical Trials; visit @ Malignant Mesothelioma Emerging Therapies and Key Players- https://www.delveinsight.com/sample-request/malignant-mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Malignant Mesothelioma : Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Malignant Mesothelioma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Pegargiminase - Polaris Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Niraparib: Merck
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. YS110: Ys Therapeutics
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. IAG933: Novartis
18. Drug profiles in the detailed report…..
19. Preclinical and Discovery Stage Products
20. Drug name: Company name
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Malignant Mesothelioma Key Companies
24. Malignant Mesothelioma Key Products
25. Malignant Mesothelioma - Unmet Needs
26. Malignant Mesothelioma - Market Drivers and Barriers
27. Malignant Mesothelioma - Future Perspectives and Conclusion
28. Malignant Mesothelioma Analyst Views
29. Malignant Mesothelioma Key Companies
30. Appendix

For further information on the Malignant Mesothelioma Pipeline Segmentation, reach out @ Malignant Mesothelioma Market Drivers and Barriers- https://www.delveinsight.com/sample-request/malignant-mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Yash Bhardwaj

info@delveinsight.com

This release was published on openPR.